Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

NCT03798314 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Nervous System Lymphoma
Recurrent Primary Vitreoretinal DLBCL
Refractory Nervous System Lymphoma
Refractory Primary Vitreoretinal DLBCL

Interventions

BIOLOGICAL: Nivolumab
DRUG: Pomalidomide

Sponsor

Mayo Clinic

Collaborators

[object Object]